Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review

Publisher： Bentham Science Publishers

E-ISSN： 1875-6360|8|3|209-226

ISSN： 1573-3971

Source： Current Rheumatology Reviews, Vol.8, Iss.3, 2012-08, pp. : 209-226

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

IL-6 Signaling and its Blockade with a Humanized Anti-Interleukin-6 Receptor Antibody in Rheumatoid Arthritis: Advent of a New and Innovative Therapeutic Drug, Tocilizumab

By  

Current Rheumatology Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 288-300

Bentham Science Publishers

Access to resources Recommend Favorite

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

By Hirano Toru  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 298-302

Springer Publishing Company

Access to resources Recommend Favorite

Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: areportofthree cases

By Komaba Hirotaka   Nakazawa Takashi   Yamaguchi Yutaka   Kumagai Shunichi   Fukagawa Masafumi  

NDT PLUS, Vol. 1, Iss. 6, 2008-12 ,pp. : 423-426

Oxford University Press

Access to resources Recommend Favorite

Apoptosis in Immune-Mediated Liver Diseases

By  

Digestive Diseases, Vol. 28, Iss. 1, 2010-05 ,pp. : 144-149

Karger

Access to resources Recommend Favorite

The OPTION trial: inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis

By Ramos-Remus Cesar   Muriel-Vizcaino Rodolfo  

Future Rheumatology, Vol. 3, Iss. 5, 2008-10 ,pp. : 429-434

Future Medicine

Access to resources Recommend Favorite